1.Date of the board of directors resolution:2024/03/11
2.Name and title of the managerial officer with permission to engage in competitive conduct:
Heidi Wang/ CEO
Ming-Tain Lai/ Chief Scientific Officer
Colin Kao/ Finance director
3.Items of competitive conduct in which the officer is
permitted to engage:
Heidi Wang/ CEO:
(1)Representative of institutional director, Amaran Biotechnology, Inc.
(2)Representative of institutional director, OBIGEN PHARMA, Inc.
(3)Representative of institutional director, OBI Pharma Australia Pty Ltd
(4)Representative of institutional director, OBI Pharma USA, Inc.
(5)Consultant of Biomedical Translation Research Center, Academia Sinica
(6)Director of Fu Jen University Foundation
Ming-Tain Lai/ Chief Scientific Officer:
(1)Representative of institutional director, Amaran Biotechnology, Inc.
(2)Representative of institutional director, AP Biosciences, Inc.
(3)Representative of institutional director, OBI Pharma Australia Pty Ltd
Colin Kao/ Finance director:
(1)Representative of institutional director, OBI Pharma USA, Inc.
(2)Supervisor, OBIGEN PHARMA, Inc.
4.Period of permission to engage in the competitive conduct: Duration of serving as managerial officer of the Company
5.Circumstances of the resolution (please describe the results of voting in accordance with Article 32 of the
Company Act):
The board of directors approved the proposal unanimously with no changes.
6.If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and
title of the managerial officer (if it is not the operator of a mainland China enterprise, please enter
“N/A” below):N/A
7.Company name of the mainland China enterprise and the
officer’s position in the enterprise: N/A
8.Address of the mainland China enterprise: N/A
9.Operations of the mainland China enterprise: N/A
10.Impact on the company’s finance and business: None
11.If the managerial officer or director has invested in
the mainland China enterprise, the monetary amount of the
investment and the officer or director’s shareholding ratio: N/A
12.Any other matters that need to be specified: None